Skip to main content
. 2023 Aug 31;18(2):264–274. doi: 10.1093/ecco-jcc/jjad146

Figure 2.

Figure 2

Clinical outcomes [ie, clinical remission, clinical response, and corticosteroid-free remission] at OLE Weeks 46 and 94 in patients on continuous ozanimod who entered the OLE in clinical response. [A] OC analysis. [B] NRI analysis. Denominators for the OC analyses were based on the numbers of patients who completed OLE Week 46 or 94 and had data available for the endpoints in question. Denominators for the NRI analyses were based on the numbers of patients who completed OLE Week 46, completed OLE Week 94, or discontinued ozanimod treatment. aClinical remission is defined as an RBS = 0 point and an SFS ≤1 point [and a decrease of ≥1 point from the baseline SFS] and an endoscopy subscore ≤1 point. bClinical response is defined as a reduction from baseline in the 3-component Mayo score [sum of the RBS, SFS, and endoscopy subscore] of ≥2 points and ≥35%, and a reduction from baseline in the RBS of ≥1 point or an absolute RBS of ≤1 point. cCorticosteroid-free remission is defined as clinical remission while off corticosteroids for ≥12 weeks. NRI, nonresponder imputation; OC, observed case; OLE, open-label extension; RBS, rectal bleeding subscore; SFS, stool frequency subscore.